E
Empros Pharma
Pharmaceutical treatments targeting overweight and obesity with advanced release formulations for improved safety and efficacy
About Empros Pharma
Empros Pharma is a pharmaceutical company focused on developing treatments for overweight and obesity. The company's flagship product, EMP16, is currently undergoing efficacy proof of concept clinical trials, having already demonstrated a best-in-class safety profile and improved blood glucose control in early phase trials. Empros Pharma serves a market that includes overweight and pre-diabetic individuals who have limited safe and effective treatment options. The business model revolves around the development and commercialization of advanced modified release formulations that offer immediate, gastroresistant, and delayed release fractions for improved tolerability and targeted drug release. Empros Pharma generates revenue through the sale and licensing of its pharmaceutical products. The company operates in the healthcare and pharmaceutical sectors, leveraging a cross-disciplinary team of experts in nutrition, metabolism, obesity, and clinical trials to drive innovation and development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Solna kommun, Sweden
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 26.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | May 2023 | $9.7M | $39M | Flerie Invest | ↗ |
| SERIES AEquity / VC | Jul 2019 | $4.8M | $19M | Flerie Invest | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Empros Pharma is 1.7K monthly website visits, up 91% over the last three months. Empros Pharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Flerie Invest
Other known investors2 additional known investors
Uppsala University
KI Science Park
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Empros Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Empros Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.